These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38943392)

  • 1. Higher Cerebrospinal Fluid Levels of Amyloid-β40 Following Traumatic Brain Injury Relate to Confrontation Naming Performance.
    Howard E; Moody JN; Prieto S; Hayes JP;
    J Alzheimers Dis; 2024; 100(2):539-550. PubMed ID: 38943392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App
    Andersson E; Schultz N; Saito T; Saido TC; Blennow K; Gouras GK; Zetterberg H; Hansson O
    Alzheimers Res Ther; 2023 Mar; 15(1):64. PubMed ID: 36964585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury.
    Mohamed AZ; Cumming P; Srour H; Gunasena T; Uchida A; Haller CN; Nasrallah F;
    Neuroimage Clin; 2018; 19():716-726. PubMed ID: 30009128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injury.
    van Amerongen S; Das S; Kamps S; Goossens J; Bongers B; Pijnenburg YAL; Vanmechelen E; Vijverberg EGB; Teunissen CE; Verberk IMW
    Neurobiol Aging; 2024 Sep; 141():121-128. PubMed ID: 38908030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing neuropsychological, typical, and ADNI criteria for the diagnosis of mild cognitive impairment in Vietnam-era veterans.
    Ly MT; Adler J; Ton Loy AF; Edmonds EC; Bondi MW; Delano-Wood L;
    J Int Neuropsychol Soc; 2024 Jun; 30(5):439-447. PubMed ID: 38263745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
    Li G; Iliff J; Shofer J; Mayer CL; Meabon J; Cook D; Pagulayan KF; Raskind MA; Zetterberg H; Blennow K; Peskind ER
    Neurology; 2024 Apr; 102(7):e209197. PubMed ID: 38478804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers.
    Weiner MW; Harvey D; Landau SM; Veitch DP; Neylan TC; Grafman JH; Aisen PS; Petersen RC; Jack CR; Tosun D; Shaw LM; Trojanowski JQ; Saykin AJ; Hayes J; De Carli C;
    Alzheimers Dement; 2023 Mar; 19(3):884-895. PubMed ID: 35768339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
    Korecka M; Figurski MJ; Landau SM; Brylska M; Alexander J; Blennow K; Zetterberg H; Jagust WJ; Trojanowski JQ; Shaw LM;
    Clin Chem; 2020 Apr; 66(4):587-597. PubMed ID: 32087019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.